Related Experiment Video
Updated: Aug 22, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Serotonin-releasing agents with reduced off-target effects.
Felix P Mayer1,2, Marco Niello3, Daniela Cintulova4
1Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Waehringer Strasse 13a, 1090, Vienna, Austria. felixpmayer@gmail.com.
New cathinone derivatives selectively release serotonin (5-HT), offering potential treatments for depression and anxiety. These compounds show reduced risk for abuse and side effects compared to existing therapies.
Area of Science:
- Neuroscience
- Psychopharmacology
- Medicinal Chemistry
Background:
- Increasing extracellular serotonin (5-HT) levels can alleviate symptoms of depression and anxiety disorders.
- Current 5-HT releasing drugs have risks of abuse and side effects.
- Novel therapeutic strategies are needed for mood and anxiety disorders.
Purpose of the Study:
- To identify novel compounds that selectively increase extracellular 5-HT.
- To evaluate the safety and efficacy profile of novel 5-HT releasing agents.
- To explore potential treatments for depression and anxiety-related disorders.
Main Methods:
- Screening of S-enantiomers of ring-substituted cathinones for 5-HT release.
- In vitro and in vivo assessment of 5-HT releasing activity.
- Evaluation of behavioral effects in preclinical models.
- Assays for dopamine release and off-target activity at monoamine transporters.
Main Results:
- S-enantiomers of specific cathinones demonstrated a preference for releasing 5-HT ex vivo and in vivo.
- These compounds exhibited 5-HT-associated effects in behavioral models.
- Lead compounds showed minimal dopamine release and reduced off-target activity, suggesting low abuse potential and fewer adverse events.
Conclusions:
- Novel ring-substituted cathinone S-enantiomers are promising lead compounds for increasing brain 5-HT.
- These agents may offer a safer therapeutic alternative for treating depression and anxiety disorders.
- Further research is warranted to explore their clinical utility.
More Related Videos
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: Overview